John  Woock net worth and biography

John Woock Biography and Net Worth

CMO of Axonics
Dr. Woock has a Ph.D. in Biomedical Engineering from Duke University, focused on neural stimulation to control urinary function. He is the coinventor of several technologies in the field of urology. Dr. Woock was previously a Stanford Biodesign Fellow and an Engagement Manager at McKinsey & Company.

What is John Woock's net worth?

The estimated net worth of John Woock is at least $5.49 million as of January 31st, 2024. Dr. Woock owns 77,403 shares of Axonics stock worth more than $5,494,065 as of November 23rd. This net worth evaluation does not reflect any other investments that Dr. Woock may own. Additionally, Dr. Woock receives a salary of $888,200.00 as CMO at Axonics. Learn More about John Woock's net worth.

How old is John Woock?

Dr. Woock is currently 41 years old. There are 7 older executives and no younger executives at Axonics. The oldest executive at Axonics is Mr. Raymond W. Cohen, Co-Founder, Chief Executive Officer and Director, who is 65 years old. Learn More on John Woock's age.

What is John Woock's salary?

As the CMO of Axonics, Inc., Dr. Woock earns $888,200.00 per year. There are 3 executives that earn more than Dr. Woock. The highest earning executive at Axonics is Mr. Raymond W. Cohen, Co-Founder, Chief Executive Officer and Director, who commands a salary of $1,750,000.00 per year. Learn More on John Woock's salary.

How do I contact John Woock?

The corporate mailing address for Dr. Woock and other Axonics executives is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. Axonics can also be reached via phone at (949) 396-6322 and via email at [email protected]. Learn More on John Woock's contact information.

Has John Woock been buying or selling shares of Axonics?

John Woock has not been actively trading shares of Axonics during the last ninety days. Most recently, John Woock sold 15,899 shares of the business's stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $67.74, for a transaction totalling $1,076,998.26. Following the completion of the sale, the executive vice president now directly owns 77,403 shares of the company's stock, valued at $5,243,279.22. Learn More on John Woock's trading history.

Who are Axonics' active insiders?

Axonics' insider roster includes Juliet Bakker (Director), Raymond Cohen (Co-Founder, Chief Executive Officer and Director), Danny Dearen (Insider), Alfred Ford, Jr. (Insider), Kari Keese (CFO), Jane Kiernan (Director), Esteban Lopez (Director), Robert Mcnamara (Director), Karen Noblett (Insider), Rinda Sama (COO), and John Woock (CMO). Learn More on Axonics' active insiders.

Are insiders buying or selling shares of Axonics?

During the last year, insiders at the sold shares 8 times. They sold a total of 92,797 shares worth more than $6,275,226.67. The most recent insider tranaction occured on October, 2nd when CFO Kari Leigh Keese sold 2,961 shares worth more than $205,523.01. Insiders at Axonics own 1.9% of the company. Learn More about insider trades at Axonics.

Information on this page was last updated on 10/2/2024.

John Woock Insider Trading History at Axonics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2024Sell15,899$67.74$1,076,998.2677,403View SEC Filing Icon  
1/31/2023Sell7,570$61.14$462,829.8069,281View SEC Filing Icon  
1/17/2023Sell30,215$67.34$2,034,678.1045,976View SEC Filing Icon  
9/8/2022Sell7,500$75.00$562,500.0045,976View SEC Filing Icon  
8/25/2022Sell7,500$72.95$547,125.0045,976View SEC Filing Icon  
8/10/2022Sell15,000$69.71$1,045,650.0053,476View SEC Filing Icon  
2/3/2022Sell6,251$48.25$301,610.75View SEC Filing Icon  
11/15/2021Sell5,000$60.48$302,400.00View SEC Filing Icon  
9/1/2021Sell8,443$74.73$630,945.39View SEC Filing Icon  
8/17/2021Sell25,000$67.00$1,675,000.0049,534View SEC Filing Icon  
2/25/2021Sell10,000$50.82$508,200.0060,161View SEC Filing Icon  
2/1/2021Sell1,917$51.36$98,457.1263,319View SEC Filing Icon  
1/28/2021Sell15,000$53.23$798,450.0063,319View SEC Filing Icon  
1/26/2021Sell1,893$53.58$101,426.9472,783View SEC Filing Icon  
11/27/2020Sell10,000$44.67$446,700.0077,348View SEC Filing Icon  
8/28/2020Sell10,000$43.45$434,500.0072,348View SEC Filing Icon  
2/25/2020Sell10,000$35.87$358,700.0077,348View SEC Filing Icon  
1/28/2020Sell15,000$30.06$450,900.0064,681View SEC Filing Icon  
12/2/2019Sell15,000$23.46$351,900.0080,181View SEC Filing Icon  
See Full Table

John Woock Buying and Selling Activity at Axonics

This chart shows John Woock's buying and selling at Axonics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Axonics Company Overview

Axonics logo
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Read More

Today's Range

Now: $70.98
Low: $70.98
High: $70.98

50 Day Range

MA: $70.09
Low: $68.72
High: $70.98

2 Week Range

Now: $70.98
Low: $55.09
High: $71.05

Volume

N/A

Average Volume

571,295 shs

Market Capitalization

$3.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82